3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
5
Neoplasm Metastasis
4
Breast Neoplasms
4
Lung Neoplasms
3
Colorectal Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Multiple Myeloma
2
Lymphoma
2
Glioblastoma
2
Urinary Bladder Neoplasms
1
Stroke
1
Stress Disorders, Post-Traumatic
1
Recurrence
1
Rectal Neoplasms
1
Ovarian Neoplasms
1
Neurologic Manifestations
1
Myelodysplastic Syndromes
1
Motor Activity
1
Melanoma
1
Margins of Excision
1
Malignant Solid Neoplasm
1
Malignant Female Reproductive System Neoplasm
1
Localized Head and Neck Carcinoma
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Kidney Neoplasms
1
Inflammatory Breast Neoplasms
1
Hematologic Neoplasms
1
Fallopian Tube Neoplasms
1
Interventions
Paclitaxel
10
Carboplatin
6
Bevacizumab
5
liposomal doxorubicin
4
Topotecan
3
Cyclophosphamide
3
pembrolizumab
2
oregovomab
2
olaparib
2
niraparib
2
fludarabine
2
Nivolumab
2
Drug Therapy
2
trastuzumab deruxtecan
1
rucaparib
1
ribociclib
1
palbociclib
1
mirvetuximab soravtansine
1
isoquercitrin
1
irinotecan sucrosofate
1
fludarabine phosphate
1
denileukin diftitox
1
anlotinib
1
Tinzaparin
1
Saline Solution
1
Propranolol
1
Preoperative Exercise
1
Platinum
1
Palliative Care
1
Neoadjuvant Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
Palliative Care
×
90 days
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled